September 21-23, 2020 | 10:00AM EDT | 2:00PM UTC*
*Program is in development and subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
The field of cancer immunology is moving at a rapid pace, with discoveries based on T cell biology and T cell targeted therapeutics eliciting real clinical successes and excitement about the future of cancer care. However, as only twenty percent of patients respond to T cell targeted therapeutics, further work must be done to harness the power of immunology in cancer care. Recent research has shown that myeloid cells create major roadblocks to cancer eradication by promoting immune suppression, angiogenesis and resistance to immune therapy. Advances in the science of these diverse cell types, roles and mechanisms governing myeloid cells in cancer, along with the recent developments of myeloid cell targeted therapeutics, has generated significant interest in the academic and pharmaceutical communities. Conferences that gather experts to focus discussion exclusively on roles of myeloid cells and innate immunity in cancer will help to move our understanding of cancer immune suppression and the field of cancer immune therapy forward. This virtual conference will present the latest developments in our understanding of the origins and contributions of various myeloid cell subsets to tumor growth and metastasis. Additionally, this meeting will challenge paradigms about macrophage and granulocyte origins in tumors, about links between metabolism and function, and about mechanisms by which myeloid cells control immunity. The program will also feature the latest clinical studies of myeloid cell targeted therapeutics in cancer which will stimulate new ideas, collaborations and advance development of new cancer immune therapeutics.
Program is intended for scientific researchers and clinical audiences.
Join us for this landmark virtual event, brought to you by Keystone Symposia.
Regular Registration Rate: $275 USD
Student Registration Rate: $150 USD
Abstract Submission: Passed
Graduate students and postdoctoral fellows, as well as individuals from low- and middle- income countries (all career stages) working in science and medicine related fields, are eligible to apply for a FREE registration code.
Find out more about financial aid opportunities here!
Showcase your work to global audiences on the eSymposia platform!
ePoster presenters will be provided with their own dedicated page on the event website to display their work in multiple formats and interact with meeting participants. ePoster features include:
To submit your work for an ePoster presentation, and to be considered for short talk selection, complete the event registration process and you will be given access to the “Submit an Abstract” tab on the event homepage.
Speaking at this eSymposia
Simon T. Barry
University of Verona, Italy
David A. Cheresh
University of California, San Diego, USA
Lisa M. Coussens
Oregon Health & Science University, USA
David G. DeNardo
Washington University Medical School, USA
Cold Spring Harbor Laboratory, USA
Dmitry I. Gabrilovich
Singapore Immunology Network, Singapore
Dana-Farber Cancer Institute, USA
Nagy A. Habib
Imperial College London and MiNA Therapeutics, UK
The Salk Institute for Biological Studies, USA
La Jolla Institute for Immunology, USA
Dartmouth College, USA
Rosandra Natasha Kaplan
NCI, National Institutes of Health, USA
Mount Sinai School of Medicine, USA
New York University, USA
Brenda C. O'Connell
Infinity Pharmaceuticals, Inc., USA
Jeffrey W. Pollard
Queen's Medical Research Institute, UK
Gwendalyn J. Randolph
Washington University, USA
University of Utah, USA
Michael C. Schmid
Liverpool University, UK
Light Chain Bioscience, Switzerland
University of Eastern Piedmont, Italy
Jo A. Van Ginderachter
VIB-Vrije Universiteit Brussel, Belgium
Judith A. Varner
University of California, San Diego, USA
Robert H. Vonderheide
University of Pennsylvania, USA
University of Michigan, USA
Subscribe to receive updates to the program for this meeting.
Live ePanel Disucssion
Editors Attending This Meeting
Funding for this conference was made possible (in part) by 1R13CA254451-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.